Looking at top Wall Street opinions, Celgene Corporation (NASDAQ: CELG) has recently made its way into the research list of Jefferies – signaling that their analyst’s rating adjustment is noteworthy. This stock was downgraded to a rating of Hold in the eyes of Jefferies, whereas its previous rating was Buy in the eyes of Jefferies, as reported on Friday, February 1st, 2019. Another heavy-hitting research note was published by Robert W. Baird on Friday January 4th, 2019, with this firm upgrading CELG to an updated rating of Outperform from its previous rating of Neutral. In the past six months and three months of trading, shares of Celgene Corporation (CELG) have moved by -6.43% and 16.75%, respectively.
Brokerage Updates Related to Celgene Corporation (CELG) Stock
This publicly-traded organization generated gains of 3.13% over the last 5 sessions. Right now, this stock is the subject of 21 analysts’ evaluations, who – on average – have given this company’s shares a Buy rating. Not a Single analyst have given underperform rating or sell rating, and 6 have given a rating of Buy or better. Based on the 21 stock market experts following this company, the average 12-month price target is $97.66. Moreover, individual price targets range between $84.00-$106.00. With its recent move to $101.00, we can see that these firms project this stock will loss by -3.87% in one year.
Updates from Celgene Corporation (CELG) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 0.10% rise since the beginning of the calendar year. A Director at Celgene Corporation (CELG) sold off some of its shares in a transaction that was finalized on Feb 07. Similarly, MARIO ERNEST sold 12,000 shares of the organization’s stock at $92.32 apiece and racked up $1,107,888 in earnings from the sale. Now, MARIO ERNEST holds 44,413 shares of the company following the exchange. A Director of the organization named CASEY MICHAEL D, was engaged in a transaction that occurred on Jun 07 that managed to be worth $1,024,010 from the sale of 13,000 common shares at a price of $78.77 per individual share.
Celgene Corporation (NASDAQ:CELG) Results in the Pipeline
The next scheduled release of financial results for Celgene Corporation will be for the Dec-18 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be $2.32. In the same vein, they expect sales for the quarter to amount to $3,988.21 million.
Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $4,037.00 million in revenue alongside EPS at $2.39. On average, the analyst projection was calling for $3,892.00 million with $2.29 per share in earnings, respectively. In the preceding quarter, this company’s revenue reached $3,814.00 million, with earnings per share ending up at $2.16.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) experienced a gain of 4.16% from the closing price in the previous trading day. That boost the price to $3.76 per share, as observed on March 7th, 2019, at a time when the total trading volume reached 4,526,465 shares of stock – compared to the typical average of 2.17M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $8.21.
Pricing Indications for AcelRx Pharmaceuticals, Inc. (ACRX)
This organization has had a price-to-earnings ratio of in the last year. In the most recent trading session, the daily high was $3.8, bringing the per-share value 4.16% high its 52-week high and about -25.54% more expensive than its 52-week low. Meanwhile, it gained 2.75 from its observable 50-day simple moving average. Right at this moment, the per-share value is 16.80% higher than the mean per-share price over the last 200 days in the market.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) In-Depth Brokerage Insights
We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 2 have a Buy rating, 5 have an outperform rating, while 2 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 2.00, based on information from Thomson Reuters.
ACRX Stock Value Potential
In trading activity as of late, this stock’s value was 3.22 up from its 200 day moving average, while also 38.10% up when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $7.00-$10.00. The market value for the entire organization reached 281.77M. After the trading day started off at the price of $3.76, these shares nearly bottomed out at its low price of $3.3601 and nearly peaked at $3.8 as its full-day high price. In the last trading session, the price ended the day at $3.61. The institutional holdings related to this organization account for 1.70%, and the Beta factor is now 2.16. This company’s RSI (Relative Strength Index) managed to hit 69.45.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Analyst Points of Focus
AcelRx Pharmaceuticals, Inc. (ACRX) has found itself inside of Credit Suisse’s research list, so their analyst rating adjustment is worth taking note of. This stock was Initiated to Outperform, by Credit Suisse, as garnered from a news report on Friday February 15th, 2019. An additional helpful research note was sent out by B. Riley FBR’s on Tuesday October 23rd, 2018. The brokerage decided to initiated ACRX to Buy.